Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + docetaxel after failure of first-line chemoimmunotherapy in driver-negative advanced NSCLC
ChiCTR2200065477Phase 4Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Nov 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
camrelizumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200065477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065477.